Humira Biosimilars Prepare For US Competition In 2023
Landmark LOE Opportunity Looms, With Multiple Adalimumab Launches Expected
Executive Summary
The advent of biosimilar competition to Humira in the US in 2023 represents the largest loss-of-exclusivity opportunity ever for the off-patent industry. But with a host of biosimilar sponsors awaiting launches throughout the year, it remains to be seen how competition will play out.
You may also be interested in...
At The Edge Of The Cliff: Five Blockbuster Drugs Set To Lose US Patent Exclusivity In 2023
With the advent of 2023, comes the start of the industry’s next patent cliff, with five products that reached billions in sales at their peak set to lose US patent exclusivity during the year. Scrip takes a look into how the affected big pharma firms are preparing for anticipated market erosion and which generic and biosimilar companies are positioned to benefit the most.
What Aspects Will Give Humira Biosimilars The Edge In 2023?
With multiple Humira biosimilars slated for launch in the US next year, some simultaneously, a Vizient survey provides some insights into what could be the most important differentiating aspects. Generics Bulletin speaks to Steven Lucio, Vizient senior principal of pharmacy solutions, about the findings.
Alvotech Bullish As Facility Deficiencies Hold Up Humira Biosimilar Again
Already approved in the EU, Norway, Iceland, Lichtenstein, the UK, Switzerland, and Canada, Alvotech’s AVT02 high-concentration biosimilar to Humira (adalimumab) will not be greenlit by the USFDA until the Icelandic firm resolved manufacturing deficiencies.